Increased Adsorption Membranes During Cardiopulmonary Bypass

NACompletedINTERVENTIONAL
Enrollment

340

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

January 15, 2022

Study Completion Date

January 15, 2022

Conditions
Cardiopulmonary BypassCardiac Surgery Associated - Acute Kidney InjurySystemic Inflammatory Response SyndromeAcute Kidney Injury
Interventions
DEVICE

oXiris®

"oXiris® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[oXiris® (Baxter Gambro)\].~Blood flow between 200-250 mL/min will be derivatised from the CPB circuit (arterial positive pressure line just after the oxygenator) into the PrismafleX eXeed™, so that it all flows thru the oXiris® membrane and returned to the CPB circuit into the venous reservoir just before the oxygenator. oXiris® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."

Trial Locations (3)

08916

Hospital German Trias i Pujol, Badalona

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

08907

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat

All Listed Sponsors
collaborator

Hospital Germans TrÃ-es i Pujol de Badalona

UNKNOWN

collaborator

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

UNKNOWN

collaborator

Baxter Healthcare Corporation

INDUSTRY

collaborator

Instituto de Salud Carlos III

OTHER_GOV

lead

Hospital Universitari de Bellvitge

OTHER

NCT02518087 - Increased Adsorption Membranes During Cardiopulmonary Bypass | Biotech Hunter | Biotech Hunter